Vagus nerve stimulation to improve ankle muscle activity and posture in Parkinson's disease
Official title: The Effects of Vagus Nerve Stimulation on Intrinsic Lower Leg Spinal Motoneuron Excitability in Parkinson's Disease.
Run by University of Minnesota · NCT07226284 · Data updated 2026-11-12
This project will test whether non-invasive vagus nerve stimulation at the neck can improve ankle muscle activation, walking, and balance in people with Parkinson's disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 21 Years to 76 Years |
| Sex | All |
| Enrollment | 75 (estimated) |
| Sponsor | University of Minnesota Academic / other |
| Locations | 1 site (Minneapolis, Minnesota) |
| Status | Recruiting |
| Started | February 10, 2026 |
| Main results expected | January 2029 |
| Study ends | January 2029 |
| Registry record updated | October 20, 2026 |
| Trial ID | NCT07226284 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with idiopathic Parkinson's disease who can walk more than 50 meters without an assistive device, are on stable medications, and can provide informed consent in English.
✕Probably not a fit
People with atypical parkinsonian disorders, recent stroke or traumatic brain injury, severe musculoskeletal gait limitations, significant cognitive impairment, pregnancy, or recent substance abuse are unlikely to benefit or are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study compares firing properties of ankle extensor motor units and persistent inward currents (PICs) in people with Parkinson's disease versus age- and sex-matched healthy adults. Researchers will record muscle activity and postural responses during standing and walking tasks to link changes in PICs to postural control deficits. The protocol includes acute non-invasive vagus nerve stimulation (nVNS) at the neck to determine whether stimulation modifies PICs and improves muscle activation and balance. Results will provide preliminary physiological and clinical data to support larger clinical trials if nVNS shows beneficial effects.
Why it matters
Potential benefit: If successful, nVNS could become a non-invasive option to improve ankle muscle activation and reduce balance problems and fall risk in people with Parkinson's disease.
How similar studies have gone: Non-invasive VNS has produced promising physiological signals in preclinical work and small human studies for other conditions, but it remains unproven for improving postural control in Parkinson's disease.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of idiopathic Parkinson's disease, * On stable medication for the preceding month and anticipated over the next 3 months, * Able to ambulate without the use of an assistive device for more than 50 meters. Control Cohort: * Age (± 3 years) and sex distribution matched to the PD cohort, * Able to ambulate without the use of an assistive device for more than 50 meters. Exclusion Criteria: * Failure to demonstrate capacity to consent (based on UBACC and/or MacArthur-CR), * History of significant neurological disorder (besides PD in the PD group), * History of stroke, traumatic brain injury, intracranial aneurysm, intracranial hemorrhage, brain tumor or atypical parkinsonian disorder, * Severe orthopedic or other related musculoskeletal pathology that has significant adverse effects on gait, * Women who are pregnant or may be pregnant, * Insufficient comprehension of the English language, * History of substance abuse in past 2 years; Additional exclusion criteria for VNS experiment * Pain at the nVNS treatment site (e.g., dysesthesia, neuralgia, cervicalgia); * Lesion (including lymphadenopathy), previous surgery (including carotid endarterectomy or vascular neck surgery) or abnormal anatomy at the stimulation site (open wound, rash, infection, swelling, cut, sore, drug patch, surgical scar\[s\]); * Known or suspected severe atherosclerotic cardiovascular disease, severe carotid artery disease (e.g., bruits or history of TIA or stroke), congestive heart failure, known severe coronary artery disease or prior myocardial infarction; * Abnormal baseline electrocardiogram (ECG) within the last year (e.g., second or third-degree heart block, prolonged QT interval, atrial fibrillation, atrial flutter, history of ventricular tachycardia or ventricular fibrillation); * Recent history of uncontrolled high blood pressure, bradycardia, tachycardia, or know recent history orthostatic hypotension; * Previous unilateral or bilateral vagotomy; * Implanted metal cervical spine hardware, other metallic implants or implantable medical devices such as deep brain stimulator, hearing aid implant, pacemaker, implanted cardioverter defibrillator, cranial aneurysm and/or cranial aneurysm clips, history of facial/orbital/metallic fragments, implanted electronic device, neurostimulator, valve replacements/stents, metallic implants/prostheses) near the stimulation site such as a bone plate or bone screw; * History of syncope or seizures (within the last 2 years);
Where it's running
-
Movement Disorders Laboratory
Minneapolis, Minnesota, United States Recruiting
Study contacts
- Study coordinator: Principal Investigator
- Email: cmackinn@umn.edu
- Phone: 612-625-8938
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
UX-DA003 injections for Parkinson's disease
This early-phase trial tests whether injecting UX-DA003 is safe and may help motor symptoms in people with Parkinson's whose response to standard treatments has declined.
-
Strength and dual-task training to help people with Parkinson’s improve strength and function
This trial tests three levels of physiotherapy, including progressive resistance training with and without cognitive dual-task and instability components, to see if they improve muscle strength, body composition, and physical function in adults with Parkinson’s or related syndromes.
-
Automated language analysis to help diagnose neurodegenerative diseases
A multilingual AI-powered language test is being tried to see if speech and language patterns can help differentiate Alzheimer’s, frontotemporal dementia, Lewy body dementia, and Parkinson’s from healthy aging.
-
Brain alpha-synuclein PET imaging in Parkinson's patients and healthy seniors
This open-label study tests a radioactive tracer called [18F]MK-0947 to see how it behaves in the brains of people with Parkinson's disease compared with healthy elderly volunteers.
-
Parkinson’s self-sufficiency and rehabilitation in a Czech spa setting
This intervention tests whether a Czech self-sufficiency test can be used with people with Parkinson’s disease and sees how spa-based rehabilitation affects independence, cognition, balance, and walking.
-
Spinal Mobility, Rigidity, and Kinesiophobia in Parkinson's Disease with and without TMD
This study tests whether people with Parkinson's disease who have Temporomandibular Disorders differ in spinal mobility, axial rigidity, and kinesiophobia from those without TMD.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.